Myocardial reverse remodeling: how far can we rewind?
- PMID: 26993225
- DOI: 10.1152/ajpheart.00696.2015
Myocardial reverse remodeling: how far can we rewind?
Abstract
Heart failure (HF) is a systemic disease that can be divided into HF with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF). HFpEF accounts for over 50% of all HF patients and is typically associated with high prevalence of several comorbidities, including hypertension, diabetes mellitus, pulmonary hypertension, obesity, and atrial fibrillation. Myocardial remodeling occurs both in HFrEF and HFpEF and it involves changes in cardiac structure, myocardial composition, and myocyte deformation and multiple biochemical and molecular alterations that impact heart function and its reserve capacity. Understanding the features of myocardial remodeling has become a major objective for limiting or reversing its progression, the latter known as reverse remodeling (RR). Research on HFrEF RR process is broader and has delivered effective therapeutic strategies, which have been employed for some decades. However, the RR process in HFpEF is less clear partly due to the lack of information on HFpEF pathophysiology and to the long list of failed standard HF therapeutics strategies in these patient's outcomes. Nevertheless, new proteins, protein-protein interactions, and signaling pathways are being explored as potential new targets for HFpEF remodeling and RR. Here, we review recent translational and clinical research in HFpEF myocardial remodeling to provide an overview on the most important features of RR, comparing HFpEF with HFrEF conditions.
Keywords: diastolic dysfunction; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; left ventricle hypertrophy; myocardial reverse remodeling.
Copyright © 2016 the American Physiological Society.
Similar articles
-
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.J Am Coll Cardiol. 2013 Jul 23;62(4):263-71. doi: 10.1016/j.jacc.2013.02.092. Epub 2013 May 15. J Am Coll Cardiol. 2013. PMID: 23684677 Review.
-
Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics.Cardiovasc Pathol. 2020 Nov-Dec;49:107243. doi: 10.1016/j.carpath.2020.107243. Epub 2020 May 19. Cardiovasc Pathol. 2020. PMID: 32629211 Review.
-
A novel mtDNA repair fusion protein attenuates maladaptive remodeling and preserves cardiac function in heart failure.Am J Physiol Heart Circ Physiol. 2018 Feb 1;314(2):H311-H321. doi: 10.1152/ajpheart.00515.2017. Epub 2017 Nov 3. Am J Physiol Heart Circ Physiol. 2018. PMID: 29101177 Free PMC article.
-
Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction.Circ Heart Fail. 2016 Nov;9(11):e003381. doi: 10.1161/CIRCHEARTFAILURE.116.003381. Circ Heart Fail. 2016. PMID: 27810862 Free PMC article.
-
Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.Am J Physiol Heart Circ Physiol. 2018 Oct 1;315(4):H934-H949. doi: 10.1152/ajpheart.00238.2018. Epub 2018 Jul 13. Am J Physiol Heart Circ Physiol. 2018. PMID: 30004258 Free PMC article.
Cited by
-
Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.Heart Fail Rev. 2019 May;24(3):367-377. doi: 10.1007/s10741-018-9758-0. Heart Fail Rev. 2019. PMID: 30618017 Free PMC article.
-
Autophagy modulation: a potential therapeutic approach in cardiac hypertrophy.Am J Physiol Heart Circ Physiol. 2017 Aug 1;313(2):H304-H319. doi: 10.1152/ajpheart.00145.2017. Epub 2017 Jun 2. Am J Physiol Heart Circ Physiol. 2017. PMID: 28576834 Free PMC article. Review.
-
Diet-Induced Microbiome's Impact on Heart Failure: A Double-Edged Sword.Nutrients. 2023 Feb 28;15(5):1223. doi: 10.3390/nu15051223. Nutrients. 2023. PMID: 36904222 Free PMC article. Review.
-
Novel drugs for heart rate control in heart failure.Heart Fail Rev. 2018 Jul;23(4):517-525. doi: 10.1007/s10741-018-9696-x. Heart Fail Rev. 2018. PMID: 29594814 Review.
-
Preoperative myocardial expression of E3 ubiquitin ligases in aortic stenosis patients undergoing valve replacement and their association to postoperative hypertrophy.PLoS One. 2020 Sep 18;15(9):e0237000. doi: 10.1371/journal.pone.0237000. eCollection 2020. PLoS One. 2020. PMID: 32946439 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous